Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lung Cancer Metastatic 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1Coronary Disease 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Atherosclerosis 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
evolocumab × Clear all
NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05144529 2026-05-05

TOP2101

Duke University

Phase 2 Terminated
19 enrolled 16 charts
Thoracic

Lung Cancer Metastatic

NCT06284564 2026-04-21

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed
12,301 enrolled
Endocrine

Coronary Disease, Multiple Endocrine Neoplasia Type 1

NCT04937413 2024-06-25

The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Duke University

Phase EARLY_PHASE1 Completed
32 enrolled
CNS

Glioblastoma, Glioma

NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Xinjiang Medical University

Phase 4 Unknown
620 enrolled

Neoplasms, Atherosclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡